Emergent Biosolutions Inc (EBS) News

Form 8-K - Current report

Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying...

Form 8-K - Current report

Form 8-K - Current report

Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024

GAITHERSBURG, Md., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a global company...

Wall Street Highlights: Apple Appeals Watch Ban, Tesla to Launch Updated Model Y, and More

U.S. index futures remained firm and stable in the pre-market on Wednesday, as investors closely watched the...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)

GAITHERSBURG, Md., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced...

Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing

GAITHERSBURG, Md., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today confirmed...

Form 8-K - Current report

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities